For Q1 of the fiscal year ending May 2027, revenue was 59.0 million yen, up 18.0% year-over-year. EBITDA was 236 million yen, operating income 83 million yen, ordinary income 68 million yen, and net loss attributable to owners of parent for the quarter was 10 million yen. Full-year forecasts: revenue 26,500 hundred million yen, EBITDA 1,700 hundred million yen, operating income 1,050 hundred million yen, net income 550 hundred million yen. There are three segments: Medical Care Sales, Healthcare Sales, and Healthcare Marketing. Note: the consolidated quarterly statement of cash flows is not prepared.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2934","jir_company_name":"J Frontier Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2934-20261015-01.pdf","jir_short_summary":"For Q1 of the fiscal year ending May 2027, revenue was 59.0 million yen, up 18.0% year-over-year. EBITDA was 236 million yen, operating income 83 million yen, ordinary income 68 million yen, and net loss attributable to owners of parent for the quarter was 10 million yen. Full-year forecasts: revenue 26,500 hundred million yen, EBITDA 1,700 hundred million yen, operating income 1,050 hundred million yen, net income 550 hundred million yen. There are three segments: Medical Care Sales, Healthcare Sales, and Healthcare Marketing. Note: the consolidated quarterly statement of cash flows is not prepared.","jir_summary":"### Summary of Results\nIn Q1 of the current fiscal year, revenue was 5,899,896 thousand yen, up 18.0% year-over-year, and EBITDA was 236,299 thousand yen, up 89.7%, contributing to significant revenue and profit growth. Operating income was 83,953 thousand yen and ordinary income was 68,885 thousand yen, returning to profitability. Net loss attributable to owners of parent for the quarter improved slightly to 10,223 thousand yen. By segment, Medical Care Sales recorded higher revenue and profit, Healthcare Sales saw EBITDA deterioration due to advertising investments, and Healthcare Marketing achieved notable EBITDA growth. Supplementary materials to the financial summary are available.\n\n### Outlook and Financial Position\nThe full-year forecasts for the fiscal year ending May 2027 are: revenue 26,500 hundred million yen, EBITDA 1,700 hundred million yen, operating income 1,050 hundred million yen, ordinary income 1,000 hundred million yen, and net income attributable to owners of parent 550 hundred million yen. These forecasts assume the impact of business combinations including provisional accounting for the quarterly results, and actual performance may vary due to future factors. Financial position: total assets 9,594,879 thousand yen, net assets 1,498,466 thousand yen, and equity ratio 12.5% (previous period 12.7%).","jir_financial_highlights":"Revenue: 5,899,896 thousand yen (Year-over-Year +18.0%)\nEBITDA: 236,299 thousand yen (Year-over-Year +89.7%)\nOperating Income: 83,953 thousand yen (Prior year same quarter was -17,239 thousand yen)\nOrdinary Income: 68,885 thousand yen (Prior year same quarter was -4,982 thousand yen)\nNet Loss Attributable to Owners of Parent (quarter): -10,223 thousand yen (Prior year same quarter was -36,020 thousand yen)\nFull-year Revenue Forecast: 26,500 hundred million yen (Year-over-Year Unknown)\nFull-year EBITDA Forecast: 1,700 hundred million yen (Year-over-Year Unknown)","jir_category":"","jir_hashtags":"#JFrontier, #FinancialResults, #BusinessSegments","jir_key_figures":"Revenue: 5,899,896 thousand yen (Year-over-Year +18.0%)\nEBITDA: 236,299 thousand yen (Year-over-Year +89.7%)\nOperating Income: 83,953 thousand yen (Prior year same quarter -17,239 thousand yen)","jir_meta_title":"J Frontier Co.,Ltd. Q1 Financial Summary for Fiscal Year Ending May 2027\uff5cRevenue 59.0 million yen \u2022 EBITDA 23.6 million yen","jir_meta_description":"Key points from J Frontier Co.,Ltd.'s Q1 financial summary for the fiscal year ending May 2027. Revenue up 18.0% YoY, EBITDA up 89.7%, full-year forecast revenue 26,500 hundred million yen. Summary of segment trends and financial position.","jir_og_title":"J Frontier Co.,Ltd.: Q1 Financial Highlights","jir_og_description":"Q1 revenue was 5,899,896 thousand yen and EBITDA was 236,299 thousand yen. Full-year forecast: revenue 26,500 hundred million yen and operating income 1,050 hundred million yen. Segment trends are also disclosed.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[5900,6000,6200,5899]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-17239,83000,76000,83953]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"ebitda_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"EBITDA Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"EBITDA\\\",\\\"data\\\":[9510,236299,300000,236299]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Medical Care Sales\\\",\\\"Healthcare Sales\\\",\\\"Healthcare Marketing\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1507998,1293110,3098786]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"EBITDA by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Medical Care Sales\\\",\\\"Healthcare Sales\\\",\\\"Healthcare Marketing\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"EBITDA\\\",\\\"data\\\":[152557, -12961, 190367]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Full-year Forecast and Actuals\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":59459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-131412","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n